Open AccessCost‐Effectiveness of Tenofovir as First‐Line Antiretroviral Therapy in India
Author(s) -
Melissa Bender,
Nagalingeswaran Kumarasamy,
Kenneth H. Mayer,
Bingxia Wang,
Rochelle P. Walensky,
Timothy P. Flanigan,
Bruce R. Schackman,
Callie A. Scott,
Zhigang Lu,
Kenneth A. Freedberg
Publication year - 2010
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/649884
Subject(s) - stavudine , zidovudine , lamivudine , medicine , tenofovir , reverse transcriptase inhibitor , nevirapine , abacavir , kharif crop , antiretroviral therapy , human immunodeficiency virus (hiv) , virology , viral load , viral disease , statistics , mathematics , virus , hepatitis b virus , field experiment
World Health Organization guidelines for antiretroviral treatment (ART) in resource-limited settings recommend either stavudine or tenofovir as part of initial therapy. We evaluated the clinical outcomes and cost-effectiveness of first-line ART using tenofovir in India, compared with current practice using stavudine or zidovudine.